Navigation Links
Magid Abou-Gharbia, Ph.D., FRSC Joins LAXAI as Scientific Advisor
Date:8/27/2009

n, women's health/bone, oncology and cardiovascular disease. His research efforts resulted in 100 U.S. patents and over 350 worldwide patents and contributed to the discovery of several marketed drugs and many compounds currently under clinical evaluation including two SNRI anti-depressants, Effexor(R) and Pristiq(R), an anticancer rapamycin derivative, Torisel(R), a broad spectrum antibiotic, Tygacil(R), and a selective estrogen receptor modulator, bazedoxifene. Dr. Abou-Gharbia received his Ph.D. in Organic Chemistry from the University of Pennsylvania. After a two year NIH Postdoctoral Fellowship at Temple University, he joined Wyeth. Dr. Abou-Gharbia will provide expertise and insight into strategies and medicinal chemistry approaches utilized in the design of novel small molecules CNS therapeutics. His numerous awards include: Induction to ACS Medicinal Chemistry Hall of Fame (2008); ACS Heroes of Chemistry (2008); Alfred Burger Award in Medicinal Chemistry (2008); Science and Technology Medal from the R&D Council of New Jersey (2008); selected among the Top 10 Scientists in New Jersey by New Jersey Business Magazine (2008); American Institute of Chemists (AIC) Chemistry Pioneer Award (2007); Fellow of the Royal Society of Chemistry (FRSC 2006); Researcher of the Year (2006) from Health Care Institute of NJ (HINJ); Trailblazer Award (2006) from Science Spectrum; Induction into the New Jersey Inventors Hall of Fame (2004); The Procter Medal (2003); ACS Earle B. Barnes Award (2001); Philadelphia Organic Chemists Club (POCC) Award (2001); Egyptian Pharmaceutical Society Drug Discovery Award (2000);Named as one of the most Prolific Inventors of the Decade by US Patent & Trade Mark (1998); ACS-Philadelphia Section Award (1997); Wyeth-Ayerst Exceptional Achievement Award (1992); and others.

LAXAI (www.laxai.com) provides services
'/>"/>

SOURCE LAXAI
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
2. EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
3. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
4. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
5. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
6. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
7. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
8. ALine, Inc. Expands Management, Adding Roger Anderson, Ph.D., as VP of Operations
9. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
10. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
11. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Findings presented at the European Organization ... of NeuroOncology (EANO) and European Society for Medical Oncology ... that EDO-S101 is effective in models of human glioblastoma ... radiotherapy (RT). [ 1 ] ... that combines the DNA damaging effect of bendamustine with ...
(Date:6/3/2015)... CIRTEC Medical Systems , a ... complex Class III implantable devices and minimally invasive devices, ... initiative aimed at identifying potentially marketable biomedical technologies developed ... moving them more efficiently from the laboratory bench to ... working with the world's largest OEMs and most innovative ...
(Date:6/3/2015)... , June 3, 2015  HireLifeScience.com, the premier ... will host its 6 th annual career ... at Raritan Center in Edison, NJ ... include Novo Nordisk, Covance, Actavis and AstraZeneca.  Additional ... be exhibiting are Johnson & Johnson, MedImmune, DSM ...
(Date:6/3/2015)... 03, 2015 Photo-Eyewear™ ( http://www.PhotoEyewear.com ... to PogoTec™, Inc. ( http://www.PogoTec.com ) to better ... device products and technologies it is developing and plans ... business divisions, PogoTec™ will provide focused resources to drive ... , , On-Track™ – There are ...
Breaking Biology Technology:Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 2Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 3Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 4CIRTEC Medical Systems to support new UT Dallas-led Initiative to deliver biomedical technologies from laboratory bench to bedside more efficiently 2AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3
... Purpose , Researchers and ... currently employ immuno- or colourimetric assays. These assays suffer from a number of limitations: , ... They are not as commonly available for novel sample matrices such ... They can be relatively costly due to the high volume of ...
... of liquid chromatography/ mass spectrometry and information dependent data acquisition function ... to quantifying their parents during metabolic stability studies. This was once ... Abstract , ... triple quadrupole ion path and is capable of doing conventional multiple ...
... very straightforward method for the analysis of the very ... and monocrotophos in water has been developed. Large volume ... RP18 HPLC column with a polar endcapping. The compounds ... mass spectrometer operated in multiple reaction-monitoring mode. The detection ...
Cached Biology Technology:Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 2Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 3Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 2Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 3Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 5Determination of Polar Organophosphorus Pesticides in Aqueous Samples by Direct Injection Using HPLC/MS/MS 2
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... 2013 The following statement is being issued by Robbins Geller Rudman ... Biosciences Securities Litigation SUPERIOR COURT OF THE STATE ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA , ... SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie S. ...
... This news release is available in German . ... the current issue of the " Journal of Clinical Investigation " ... begin to fail with increasing age. As a result, signs of ... Alzheimer,s disease, diabetes, cardiovascular disorders and cancer, increases. "Current efforts to ...
... Developing ways to treat cancer patients with drugs that kill ... one of the topics in the premiere segment of the ... Chemical Society (ACS), the world,s largest scientific society. The videos ... DVD . Titled Prized Science: Peter Stang ...
Cached Biology News:Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4Rapamycin: Limited anti-aging effects 2Rapamycin: Limited anti-aging effects 3American Chemical Society launches 2013 edition of popular Prized Science video series 2
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
SH3 Proteins II Sampler Kit 10g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: